As a patient at Seattle Cancer Care Alliance (SCCA), you will work with doctors from Fred Hutchinson Cancer Research Center and UW Medicine who are experts in myeloproliferative neoplasms (MPN) and myelodysplastic syndrome (MDS). Patients come here from across the United States and around the globe because SCCA is one of the leading centers in the world for care of patients with these diseases. We provide comprehensive, leading-edge diagnosis and treatment.
Building and Sharing Knowledge
Our doctors and scientists have made and continue to make important contributions to the understanding of MPN and MDS, from establishing the diagnosis to treating even advanced disease. They work on MPN and MDS at all levels, from basic laboratory research to medical therapy to epidemiology. Members of our team are invited to present their latest findings and treatment results at meetings around the globe, such as the annual International Symposium on Myelodysplastic Syndromes, and from there they bring back additional knowledge generated by international colleagues.
Pioneering Transplants—and Mini-Transplants
Researchers at Fred Hutchinson Cancer Research Center have special expertise in bone marrow (hematopoietic cell) transplantation, the only treatment option with the potential to cure MPN or MDS. Ours is one of the largest bone marrow transplant programs in the world.
The Hutchinson Center’s Dr. E. Donnall Thomas, MD, pioneered bone marrow transplantation and was awarded the 1990 Nobel Prize in medicine or physiology for his life-saving research.
The goal of SCCA physician-researchers is to build on these accomplishments and develop new life-saving options for all patients with serious blood diseases. MPN patients at SCCA are already benefiting from new and innovative therapies, such as bone marrow transplants following low-dose conditioning (non-myeloablative transplants or mini-transplants), immunotherapy, cord blood transplants, and other treatments.
Providing Needed Support
Over the years, tens of thousands of patients diagnosed with MPN, MDS, and other malignant and non-malignant blood disorders have come to SCCA to receive the latest treatments. We offer compassionate support during and after your care, and we are committed to helping you understand your health and treatment options because you and your family are part of the care team, too.